alpha lipoic acid
Recently Published Documents


TOTAL DOCUMENTS

1366
(FIVE YEARS 450)

H-INDEX

50
(FIVE YEARS 9)

2022 ◽  
pp. 1-9
Author(s):  
Yahya M. Hodeeb ◽  
Emad M. El-Rewiny ◽  
Abdullah M. Gaafar ◽  
Ahmed N. Zayed ◽  
Mohamed S. Hasan ◽  
...  

2022 ◽  
Vol 13 ◽  
Author(s):  
Chih-Yuan Ko ◽  
Jian-Hua Xu ◽  
Yu-Wei Chang ◽  
Yangming Martin Lo ◽  
James Swi-Bea Wu ◽  
...  

Background and objectives: This study aimed to investigate the enhancing effect of vitamin-like alpha-lipoic acid (ALA) on phagocytosis of oligomeric beta-amyloid (oAβ)1–42 in BV-2 mouse microglial cells.Methods: An in vitro model was established to investigate phagocytosis of oAβ1–42 in BV-2 cells. Transmission electron microscopy images indicated that the morphology of prepared oAβ1–42 was spherical particles. BV-2 cells treated with ALA were incubated with 5(6)-carboxyfluorescein-labeled oAβ1–42 (FAM-oAβ1–42) for 24 h, followed by flow cytometer analysis, western blotting, real-time quantitative PCR, and immunocytochemistry (ICC) analysis to assess the in vitro phagocytosis ability of oAβ1–42.Results: Alpha-lipoic acid significantly increased messenger RNA (mRNA) expression of the CD36 receptor in BV-2 cells. ICC analysis showed that ALA significantly elevated CD36 protein expression in BV-2 cells both with and without oAβ1–42 treatment. Results from the flow cytometry analysis indicated that the CD36 receptor inhibitor significantly attenuated ALA-promoted phagocytosis of FAM-oAβ1–42 in BV-2 cells. Moreover, ICC analysis revealed that ALA caused the translocation of peroxisome proliferator-activated receptor-γ (PPAR-γ), which is known to regulate the expression of CD36 mRNA in BV-2 cells. ALA also elevated both the mRNA and protein expression of cyclooxygenase-2 (COX-2), which is a key enzyme involved in the synthesis of 15-deoxy-Δ12,14-prostaglandin J2 in BV-2 cells.Conclusion: We postulated that ALA enhances oAβ1–42 phagocytosis by upregulating the COX-2/15-deoxy-Δ12,14-prostaglandin J2/PPAR-γ/CD36 pathway in BV-2 cells. Finally, future studies should be conducted with an in vivo study to confirm the findings.


2022 ◽  
Vol 134 (1) ◽  
Author(s):  
Aishwarya Nadgir ◽  
Malatesh S Pujar ◽  
Shivaprasadagouda Patil ◽  
Ashok H Sidarai

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Mahnaz Rezaei Kelishadi ◽  
Amirmansour Alavi Naeini ◽  
Fariborz Khorvash ◽  
Gholamreza Askari ◽  
Zahra Heidari

AbstractThe current study was performed to evaluate the effects of alpha-lipoic acid (ALA) supplementation on lactate, nitric oxide (NO), vascular cell adhesion molecule-1 (VCAM-1) levels, and clinical symptoms in women with episodic migraines. Considering the inclusion and exclusion criteria, ninety-two women with episodic migraines participated in this randomized, double-blind, placebo-controlled, parallel-design trial. The participants were randomly assigned to receive either 300 mg/day ALA or placebo, twice per day for 12 weeks. The primary outcomes included headache severity, headache frequency per month, and duration of attacks and the secondary outcomes included lactate (a marker of mitochondrial function), NO, and VCAM-1 serum levels were measured at baseline and the end of the intervention. At the end of the study, there was a significant decrease in lactate serum levels (− 6.45 ± 0.82 mg/dl vs − 2.27 ± 1.17 mg/dl; P = 0.039) and VCAM-1 (− 2.02 ± 0.30 ng/ml vs − 1.21 ± 0.36 ng/ml; P = 0.025) in the ALA as compared to the placebo group. In addition, the severity (P < 0.001), frequency (P = 0.001), headache impact test (HIT-6) (P < 0.001), headache dairy results (HDR) (P = 0.003), and migraine headache index score (MHIS) (P < 0.001) had significantly decreased in the intervention as compared to the control group. No significant changes were observed for NO levels and duration of migraine pains. ALA supplementation can be considered a potential adjunct treatment in patients with migraine due to its improving mitochondrial and endothelial functions and clinical symptoms.


BioMed ◽  
2021 ◽  
Vol 2 (1) ◽  
pp. 1-12
Author(s):  
Dominika Mačáková ◽  
Markéta Plchová ◽  
Lubica Cibičková ◽  
Ondřej Krystyník ◽  
David Karásek ◽  
...  

Introduction: One of the most common chronic complications of diabetes mellitus is diabetic neuropathy. The aim of the study was to elucidate the association between selected markers of oxidative stress and markers of vascular stiffness and to contribute to the understanding of the pathophysiological links between oxidative stress and micro- and macrovascular complications of diabetes. Methods: We enrolled patients with type 2 DM (n = 49), with moderate to severe diabetic polyneuropathy of lower extremities, and a control group without microvascular complications (n = 29). The neuropathy group received alpha-lipoic acid infusion therapy. Sampling was performed before and after treatment to determine the level of oxidative markers (advanced glycation end-products—AGEs, glycation products of AOPP proteins, MDA malondialdehyde and oxidized LDL), parameters of metabolic control and parameters of vascular wall stiffness were measured by sphygmomanometry. Results: After the administration of alpha-lipoic acid, we demonstrated a significant reduction in the level of three selected oxidation markers (AOPP: p < 0.001, AGE: p < 0.001, oxLDL: p < 0.05). In contrast, the level of MDA did not change significantly (p = 0.83). Throughout the group, oxLDL was significantly correlated with central BP (SBP and DBP in the aorta, p < 0.05 and <0.01) and with the augmentation index (AiX/75 bpm, p < 0.01). AOPP significantly correlated with systolic BP in the aorta (p < 0.05). We did not find significant associations in the remaining oxidation markers. Conclusion: In our study, we demonstrated a reduction in the level of oxidative markers after alpha-lipoic acid administration and also an association between markers of oxidative damage to lipids and proteins (oxLDL and AOPP) and some parameters of vascular stiffness.


2021 ◽  
Author(s):  
Hristian Staykov ◽  
Maria Lazarova ◽  
Yozljam Hassanova ◽  
Miroslava Stefanova ◽  
Lyubka Tancheva ◽  
...  

Abstract This study evaluates some of the neuromodulatory mechanisms of the memory loss preventive effect of alpha-lipoic acid (ALA) in a scopolamine (Sco)-induced rat model of an Alzheimer’s disease (AD) type dementia. Our results confirmed that Sco administration induces significant memory impairment, worsens exploratory behaviour and habituation; it increases acetylcholinesterase (AChE) activity and induces pathological monoamine content changes in the brain prefrontal cortex and hippocampus. ALA administration prevented to a large extent Sco-induced memory impairment; it also improved exploratory behaviour and preserved habituation; it decreased AChE activity, reversing it to Control group levels and corrected aberrant monoamine levels in the brain prefrontal cortex and hippocampus. According to the data available, this is the first time that ALA-induced changes in AChE and monoamine levels in the brain prefrontal cortex and hippocampus (brain structures related to learning and memory) have been demonstrated in a Sco-induced rat model of AD type dementia.


2021 ◽  
Vol 71 (Suppl-3) ◽  
pp. S526-29
Author(s):  
Muhammad Tahir ◽  
Asim Abbas ◽  
Faiz Ul Hassan Nawaz ◽  
Mohsin Raza ◽  
Atif Rafique ◽  
...  

Objective: To compared efficacy of alpha lipoic acid (antioxidant medication) and aloe vera gel together versus intralesional steroids (hydrocortisone) in management of oral submucous fibrosis by evaluating post treatment clinical features of mouth opening and burning sensation. Study Design: A prospective comparative study. Place and Duration of Study: Department of ENT, Combined Military Hospital, Malir Karachi, from Jul 2018 to Mar 2020. Methodology: Twenty-eight patients were involved in the research and were distributed into two groups, I and II. Alpha lipoid acid with aloe vera gel was given in group I and hydrocortisone was given in group II. Burning sensation and mouth opening were recorded both at start and at monthly interval later on for three consecutive months. The data collected were statistically analyzed by using SPSS-22. Results: A significant lessening in burning sensation (p<0.001) and improvement in mouth opening were noticed in both groups. However, comparison between alpha lipoic acid with aloe vera gel group versus hydrocortisone group showed almost similar results. Conclusion: Alpha lipoic acid and aloe vera gel can significantly improve oral submucous fibrosis clinically. So, these can be utilized as an alternative option in cases where intralesional steroid is poorly tolerated or is contraindicated.


2021 ◽  
Vol 17 (8) ◽  
pp. 633-636
Author(s):  
N.О. Kravchun ◽  
I.P. Dunaieva

The article presents current data from the scientific medical literature on the effective use of the R(+)-enantiomer of α-lipoic acid in various pathological conditions. The authors analyze the literature data on the comparative assessment of the activity of racemic and dextrorotatory forms of thioctic (alpha-lipoic) acid in low back pain, the effect of the R(+)-enantiomer in combination with hyperbaric oxygen therapy on the production of interleukin-6, tumor necrosis factor α and vascular endothelial growth factor in the healing of chronic ulcers of the lower extremities, as well as the use of R-α-lipoic acid in patients with mild to moderate carpal tunnel syndrome. It should be noted that recently around the world there is a tendency to gradual transition from the course treatment of diabetic neuropathy towards long-term and continuous use of pathogenetic therapies in order to maintain their positive effects. Alpha-lipoic acid is widely used in neurological practice, as evidenced by our data. Also, α-lipoic acid is actively used in gastroenterology in the treatment of chronic liver diseases. Currently, the action of α-lipoic acid is being actively studied in terms of the prevention and treatment of atherosclerosis. Based on the analyzed data, the authors concluded that it is the R(+)-enantiomer of α-lipoic acid that has a positive biological effect, and treatment with it should be carried out almost constantly, taking breaks in its intake. The duration of R-α-lipoic acid use depends on the specific clinical situation, and given the current personalized approach to treatment, as shown by the analysis of modern medical sources, people with diabetes in a state of decompensation of carbohydrate metabolism should be prescribed it for 6 months continuously with a break of 2 months and repeated courses.


2021 ◽  
Vol 19 ◽  
Author(s):  
Nihar Ranjan Das ◽  
Bhupesh Vaidya ◽  
Pragyanshu Khare ◽  
Mahendra Bishnoi ◽  
Shyam Sunder Sharma

Background: PPAR gamma co-activator 1α (PGC-1α) is known as the master regulator of mitochondrial biogenesis. It is also a co-activator of peroxisome proliferator-activated receptor-gamma (PPARγ) and plays a role in preventing mitochondrial dysfunction in several neurodegenerative disorders, including Parkinson’s disease (PD). Depletion in the levels of these proteins has been linked to oxidative stress, inflammation, and DNA damage, all of which are known to contribute to the pathogenesis of PD. Objective: In the present study, combination therapy of PPARγ agonist (GW1929) and PGC-1α activator (alpha-lipoic acid) was employed to ameliorate cognitive deficits, oxidative stress, and inflammation associated with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD. Results: Our study showed that MPTP-induced PD rats exhibited an increase in oxidative stress and inflammation, leading to cognitive deficits. Furthermore, MPTP-induced PD rats also exhibited reduced mitochondrial biogenesis in comparison to control and sham animals. Intraperitoneal administration of GW 1929 and alpha-lipoic acid in doses lower than those earlier reported individually in literature led to an improvement in the cognitive deficits in comparison to MPTP-induced PD rats. These improvements were accompanied by a reduction in the levels of oxidative stress and inflammation. In addition, an increase in mitochondrial biogenesis was also observed after the combination of these pharmacological agents. Conclusion: Our results provide a rationale for the development of agents targeting PPARγ and PGC-1α as potent therapeutics for the treatment of neurological diseases like PD.


Sign in / Sign up

Export Citation Format

Share Document